Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]

COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a fe...

Full description

Bibliographic Details
Main Authors: Wern Hann Ng, Xiang Liu, Suresh Mahalingam
Format: Article
Language:English
Published: F1000 Research Ltd 2020-08-01
Series:F1000Research
Online Access:https://f1000research.com/articles/9-991/v1
Description
Summary:COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.
ISSN:2046-1402